A major clinical trial shows that the drug, esketamine, one of the two main forms of ketamine, outperforms one of the standard treatments for treatment-resistant major depression.
Novo touts early data for next-gen oral weight loss drug as it outlines next steps
Novo Nordisk’s oral amycretin showed a 13.1% weight loss in patients after just 12 weeks in a small Phase I trial, the company revealed at
March 8, 2024